Advanced Search

 

Study ID Status Title Patient Level Data
115829 Completed An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with the AKT Inhibitor GSK2110183 in Subjects with Solid Tumors and Multiple Myeloma
115830 Completed A Double blind, Placebo controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin induced Inflammatory Response in Healthy Male Subjects Study Listed on ClinicalStudyDataRequest.com
115860 Completed An open-label, randomized, single centre, 4-way crossover study to evaluate the pharmacokinetics of single oral doses of ezogabine/retigabine in healthy adult Taiwanese subjects Study Listed on ClinicalStudyDataRequest.com
115879 Completed A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection Study Listed on ClinicalStudyDataRequest.com
115902 Completed A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin from Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects with Acne Vulgaris Study Listed on ClinicalStudyDataRequest.com
115918 Completed An open-label study to assess the immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine, Engerix™-B in adults with or without type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com
115919 Terminated An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus Study Listed on ClinicalStudyDataRequest.com
115938 Completed A multi-center, randomized, double-blind, dose-ranging study to evaluate GSK573719 in combination with fluticasone furoate, fluticasone furoate alone, and an active control of fluticasone furoate/vilanterol combination in subjects with asthma Study Listed on ClinicalStudyDataRequest.com
115951 Completed A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects with Mild to Moderate Ulcerative Colitis Study Listed on ClinicalStudyDataRequest.com
116010 Completed A Phase I, Open-label, Three-Period, Single Sequence, Crossover Study Evaluating the Drug-Drug Interaction Between Eltrombopag and Boceprevir and Between Eltrombopag and Telaprevir in Healthy Adult Subjects
116023 Completed Immunogenicity, safety and reactogenicity study of GSK Biologicals’ quadrivalent seasonal influenza candidate vaccine GSK2321138A, administered to children who previously participated in study 115345 Study Listed on ClinicalStudyDataRequest.com
116038 Completed An open label positron emission tomography study in healthy male subjects to investigate brain PDE4 engagement, pharmacokinetics and safety of single oral doses of GSK356278, using 11C-(R)-rolipram as a PET ligand(s) Study Listed on ClinicalStudyDataRequest.com
116086 Terminated A pharmacy based open study to evaluate whether pack size affects compliance for subjects diagnosed with diabetes type II who are established on metformin treatment Study Listed on ClinicalStudyDataRequest.com
116087 Active, Not Recruiting PGx420: Genetic Evaluation(exploratory and confirmatory) of efficacy and safety endpoints in pazopanib(GW786034)/sunitinib-treated patients with renal cell carcinoma (VEG108844,VEG113078)
116132 Completed A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5 mcg, Vilanterol 25 mcg, and Umeclidinium/Vilanterol 62.5/25 mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
116133 Completed A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
116134 Completed DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium bromide/Vilanterol Compared with Fluticasone propionate/Salmeterol Over 12 weeks in Subjects with COPD Study Listed on ClinicalStudyDataRequest.com
116135 Completed A multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks with COPD Study Listed on ClinicalStudyDataRequest.com
116136 Completed A multicenter, randomized, double-blind, parallelgroup study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide Inhalation Powder (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks in subjects with COPD. Study Listed on ClinicalStudyDataRequest.com
116145 Completed Genotypic analysis of baseline and nadir HCV samples from subjects enrolled in the HBI115040 Phase I clinical trial
116146 Completed A retrospective analysis of the IL28 polymorphism of HCV-infected subjects enrolled in the HBI115040 Phase 1 clinical trial
116170 Completed A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
116197 Completed A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE (LATITUDE)-TIMI 60. Study Listed on ClinicalStudyDataRequest.com
116216 Completed An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
116239 Completed An observational cohort study to assess the risk of autoimmune diseases in adolescent and young adult women aged 9 to 25 years exposed to Cervarix® in the United Kingdom

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.